Phase 3 study of addition of tislelizumab to first-line chemotherapy for advanced squamous NSCLC

Tislelizumab is a monoclonal antibody with high binding affinity for the PD-1 receptor. A phase 3 study at 46 centers in China found that addition of tislelizumab to first-line chemotherapy for advanced squamous non-small cell lung cancer was associated with significantly prolonged progression-free survival and higher objective response rate, regardless of PD-L1 expression. The safety was manageable (visual abstract).